Castle Biosciences, Inc.CSTLNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank42
3Y CAGR+10.0%
5Y CAGR-19.0%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
+10.0%/yr
vs -51.5%/yr prior
5Y CAGR
-19.0%/yr
Recent acceleration
Acceleration
+61.5pp
Accelerating
Percentile
P42
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.78% |
| Q3 2025 | -3.65% |
| Q2 2025 | -2.05% |
| Q1 2025 | 1.94% |
| Q4 2024 | 0.62% |
| Q3 2024 | -1.40% |
| Q2 2024 | 19.22% |
| Q1 2024 | 10.37% |
| Q4 2023 | 7.52% |
| Q3 2023 | 22.65% |
| Q2 2023 | 19.27% |
| Q1 2023 | 9.65% |
| Q4 2022 | 3.59% |
| Q3 2022 | 6.24% |
| Q2 2022 | 29.74% |
| Q1 2022 | 7.24% |
| Q4 2021 | 6.66% |
| Q3 2021 | 3.15% |
| Q2 2021 | -0.24% |
| Q1 2021 | 31.87% |
| Q4 2020 | 13.68% |
| Q3 2020 | 19.68% |
| Q2 2020 | -27.00% |
| Q1 2020 | -1.23% |
| Q4 2019 | 19.35% |
| Q3 2019 | 37.59% |
| Q2 2019 | 23.19% |
| Q1 2019 | -23.78% |
| Q4 2018 | 208.10% |
| Q3 2018 | -6.73% |
| Q2 2018 | 8.77% |
| Q1 2018 | 0.00% |